Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Atropine 0.05% effective in delaying myopia progression in children

01 Aug 2018

Treatment with atropine eye drops confers concentration-dependent myopia control effects in children, according to the results of the LAMP* trial. Specifically, the 0.05% concentration shows superiority in controlling spherical equivalent (SE) progression and axial length (AL) elongation over a 1-year follow-up as compared with the 0.025% and 0.01% concentrations.

A total of 438 children aged 4–12 years with myopia of at least −1.0 dioptre (D) and astigmatism of −2.5 D or less were randomized (1:1:1:1) to receive atropine eye drop at 0.05%, 0.025% or 0.01% or placebo eye drop once nightly to both eyes for 12 months. Cycloplegic refraction, AL, accommodation amplitude, pupil diameter and best-corrected visual acuity were assessed at baseline, week 2, and months 4, 8 and 12. Visual Function Questionnaire was administered at the end of treatment at 1 year.

Respective mean changes in SE and AL at 1 year, the primary study endpoint, were −0.27 D and 0.20 mm in the 0.05% atropine group, −0.46 D and 0.29 mm in the 0.025% group, −0.59 D and 0.36 mm in the 0.01% group, and −0.81 D and 0.41 mm in the placebo group (p<0.001). Corresponding reduction in accommodation amplitude were 1.98, 1.61, 0.26 and 0.32 D (p<0.001).

Pupil sizes under photopic and mesopic conditions increased respectively by 1.03 and 0.58 mm in the 0.05% atropine group, 0.76 and 0.43 mm in the 0.025% group, 0.49 and 0.23 mm in the 0.01% group, and 0.13 and 0.02 mm in the placebo group (p<0.001).

Visual acuity and vision-related quality of life were not affected in all treatment groups.

LAMP demonstrates that low-concentration atropine eye drops (0.05%, 0.025% and 0.01%) delay myopia in a concentration-dependent fashion, researchers said. Moreover, all atropine concentrations are well tolerated without apparent adverse effect on the quality of life.

Additional studies are warranted to explore the antimyopia mechanism of low-concentration atropine.

*Low-Concentration Atropine for Myopia Progression

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.